Eton Pharmaceuticals, Inc. announced on April 27 2026 that it has dosed the first patient in a pilot clinical study of its ET‑700 candidate, a proprietary extended‑release zinc acetate formulation for Wilson disease.
The study, conducted at Aarhus University Hospital in Denmark, is a double‑blinded, placebo‑controlled trial enrolling 36 healthy volunteers to compare ET‑700 with the current Galzin therapy and placebo. The trial will last four weeks and use positron emission tomography to assess intestinal copper absorption.
If the pilot shows positive safety and efficacy signals, Eton plans to launch a pivotal study in early 2027 and, upon approval, expects ET‑700 to generate more than $100 million in peak annual U.S. sales.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.